WVE

Over the past six months, Wave Life Sciences' stock (WVE) has experienced significant volatility and a general downward trend, decreasing by 36.21% over the last 12 months and 16.07% in the past month as of September 17, 2026. Key events include Q2 2026 financial results (July 30, 2026) which reported lower revenue and wider net losses, contributing to a stock decline. Positive interim data for WVE-007 in August 2026, showing improvements in body composition, along with the initiation of Phase 2a combination trials in September 2026, served as positive catalysts. The company completed its redomiciliation to Delaware in August 2026. Analyst ratings have been mixed, with some maintaining 'Buy' ratings while others cut to 'strong sell,' though the average price target was significantly higher than the trading price. Wave Life Sciences announced its participation in the Cantor 2026 Global Healthcare Conference in September 2026. Insider trading over the past 12 months showed net buying, indicating confidence from management.